Myriad Genetics, Inc.
MYGN announced today that it has launched myRisk Hereditary Cancer, a
new multi-gene diagnostic test that will provide increased sensitivity by
analyzing 25 genes associated with eight major cancers including: breast,
colorectal, ovarian, endometrial, pancreatic, prostate, gastric and melanoma.
myRisk Hereditary Cancer is being launched in a phased approach beginning with
an early-access, clinical-experience program to a limited number of medical
and scientific thought leaders followed by an expanded access program later in
the year. The Company will present extensive clinical validity data for myRisk
Hereditary Cancer at The Collaborative Group of the Americas on Inherited
Colorectal Cancer (CGA) annual meeting in October and the San Antonio Breast
Cancer Symposium in December.
The new myRisk Hereditary Cancer test represents the next generation of
hereditary cancer testing and will provide healthcare providers with clear and
actionable information to improve patient care, regardless of whether the
patient receives a positive or negative test result. Each test report will
include a genetic test result, a clinical risk and healthcare management tool
based on professional society guidelines.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in